Previous studies have shown that breast cancer patients carrying BRCA mutations may present with reduced AMH levels even before the initiation of gonadotoxic therapy, and the BRCA status has been identified as an important parameter in predicting the long-term ovarian function. This evidence concerns the gene AMH and breast cancer.